Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery.

We have evaluated the haemostatic efficacy of plasma derived, highly purified, solvent-detergent treated factor IX concentrate (Nanotiv), to which a nanofiltration step has recently been added to improve safety with regard to parvovirus B19, hepatitis A and other nonlipid enveloped viruses. Thirteen surgical procedures, including eight orthopaedic operations, were carried out using continuous infusion of Nanotiv in 10 haemophilia B patients (nine severe and one mild). Tranexamic acid was used for 11 of the 13 procedures. The mean factor IX levels on the day of surgery and postoperative days 1-3 were 0.77, 0.89, 0.80 and 0.73 IU mL(-1), respectively. The haemostatic effect was rated as normal or excellent and no blood transfusions were needed. One patient had thrombophlebitis twice at the infusion site. The remaining cases received heparin, 5 units per 100 IU of Nanotiv, and had neither superficial nor deep venous thromboembolic complications. The requirement for factor IX in the four joint replacement operations was 663 IU kg(-1) during the first 9 days, which compares favourably with previous materials. Thus, continuous infusion with this highly purified factor IX concentrate with improved viral safety is effective for surgery in haemophilia B.
AuthorsS Schulman, R Wallensten, B White, O P Smith
JournalHaemophilia : the official journal of the World Federation of Hemophilia (Haemophilia) Vol. 5 Issue 2 Pg. 96-100 (Mar 1999) ISSN: 1351-8216 [Print] ENGLAND
PMID10215956 (Publication Type: Journal Article)
Chemical References
  • Factor IX
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Drug Administration Schedule
  • Factor IX (chemistry, isolation & purification, pharmacokinetics, therapeutic use)
  • Filtration
  • Half-Life
  • Hemophilia B (drug therapy, surgery)
  • Humans
  • Infusions, Intravenous
  • Metabolic Clearance Rate
  • Microchemistry
  • Middle Aged
  • Orthopedics
  • Postoperative Complications

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: